



HIMUKA AM PHARAMA ENTERS INTO A LICENSE AGREEMENT OF ADRENOMEDULLIN

6th APRIL 2026

Himuka AM Pharma Corp. today announced that it has entered into a license agreement with Pharma Foods International Co., Ltd. regarding the bioactive peptide adrenomedullin (development code: HM101).

Under the terms of the agreement, Himuka has granted Pharma Foods International exclusive rights in Japan, South Korea, and Taiwan for the development, manufacturing, and commercialization of a novel therapeutic candidate utilizing an adrenomedullin formulation for the treatment of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL).

Furthermore, Himuka is concurrently advancing the drug development of a long-acting adrenomedullin derivative (development code: HM201). The company will continue to devote resources to the development of HM201, and remains committed to advancing new treatment options for patients with unmet medical needs worldwide.

About Adrenomedullin

Adrenomedullin is a bioactive peptide discovered in 1993 by Dr. Kitamura, Dr. Kangawa, et al. Adrenomedullin possesses diverse actions, including angiogenesis, tissue regeneration, and anti-inflammatory effects. Himuka has coded the development of adrenomedullin as HM101.

About CADASIL

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary cerebrovascular disorder caused by mutations in the *NOTCH3* gene. It is designated as an intractable disease by the Ministry of Health, Labor and Welfare in Japan. The prevalence in Japan is estimated to be 1.20 to 3.58 cases per 100,000 adults.

About Himuka

Himuka AM Pharma Cop. is a multi-asset, clinical-stage biopharmaceutical company focused on developing novel treatments for unmet needs, including refractory Inflammatory bowel disease.

Himuka has been selected for the J-Startup program by the Japan Ministry of Economy, Trade and Industry.

For more information, visit <https://www.himuka-am.com/>

Forward-Looking Statements

This press release may contain forward-looking statements.

Statements contained in this press release concerning plans, predictions, and strategies to improve future performance ("Forward-Looking Statements") are based on information currently available to Himuka's management, and inevitably involve a certain element of risk and uncertainties.

Actual results may therefore differ from those in the Forward-Looking Statements. Therefore, forward-looking statements should not be relied upon as representing Himuka's views as of any date after the date of this press release.